{
    "id": "52838446",
    "text": "Gandotinib (LY-2784544) is an experimental drug developed by Eli Lilly for treatment of cancer. It is a small molecule JAK2 (Janus kinase) inhibitor, with additional minor inhibition of STAT3. In a phase I trial, 16% of patients receiving the drug developed tumor lysis syndrome. A phase II trial is underway for patients with myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, or myelofibrosis, who had failed ruxolitinib. == References == Category:Experimental cancer drugs Category:Pyrazoles Category:Morpholines ",
    "title": "Gandotinib"
}